Cerus (CERS) Stock Price, News & Analysis

Company Overview

Cerus Corporation is a medical technology company specializing in blood safety and transfusion medicine. Founded in 1991 and headquartered in Concord, California, Cerus has pioneered pathogen reduction technology designed to improve the safety of blood products. The company focuses on reducing the risk of transfusion‐transmitted infections by targeting viruses, bacteria, and parasites that may be present in donated blood components.

The core of Cerus’s product portfolio is the INTERCEPT Blood System, which treats platelets and plasma with a combination of amotosalen and ultraviolet A (UVA) light to inactivate pathogens and residual white blood cells. This technology has received regulatory approvals in multiple markets, including the European Union, and operates under specific clearances or investigational status in other regions. By crosslinking nucleic acids, the INTERCEPT system helps maintain the functional integrity of blood components while significantly lowering the risk of transfusion reactions.

Cerus serves a global customer base that includes blood centers, hospital networks, and transfusion services across North America, Europe, and select markets in Asia. The company’s manufacturing facilities and distribution channels are structured to support both commercial supply and ongoing clinical studies. In addition to its commercial offerings, Cerus continues to invest in research and development aimed at expanding pathogen reduction into red blood cells and whole‐blood treatments, as well as exploring applications for emerging infectious threats.

Under the leadership of President and Chief Executive Officer Umberto Tedeschi, Cerus is committed to advancing transfusion safety through strategic partnerships, regulatory engagement, and innovation. The management team combines expertise in medical devices, biotechnology, and global healthcare delivery to drive commercialization efforts and support long-term growth. Cerus remains focused on enhancing patient safety and strengthening the resilience of blood systems worldwide.

Key Stats

• Today's Range: $1.35 to $1.40
• 50-Day Range: $1.23 to $1.56
• 52-Week Range: $1.12 to $2.54
• Volume: 572,339 shs
• Average Volume: 1.31 million shs
• Market Capitalization: $259.98 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.50
• Consensus Rating: Buy

Cerus Stock Analysis - MarketRank™

Cerus scored higher than 53% of companies evaluated by MarketBeat, and ranked 525th out of 933 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Cerus has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Cerus has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Cerus are expected to grow in the coming year, from ($0.08) to ($0.06) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cerus is -13.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cerus is -13.60, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cerus has a P/B Ratio of 4.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

4.41% of the float of Cerus has been sold short.

Short Interest Ratio / Days to Cover

Cerus has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Cerus has recently increased by 18.45%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cerus does not currently pay a dividend.

Dividend Growth

Cerus does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

4.41% of the float of Cerus has been sold short.

Short Interest Ratio / Days to Cover

Cerus has a short interest ratio ("days to cover") of 6.4.

Change versus previous month

Short interest in Cerus has recently increased by 18.45%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

Cerus has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.96 average news sentiment score of Medical companies.

Search Interest

Only 2 people have searched for CERS on MarketBeat in the last 30 days. This is a decrease of -60% compared to the previous 30 days.

MarketBeat Follows

4 people have added Cerus to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cerus insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 5.60% of the stock of Cerus is held by insiders.

Percentage Held by Institutions

78.37% of the stock of Cerus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

CERS Stock Analysis - Frequently Asked Questions

How have CERS shares performed this year?

Cerus' stock was trading at $1.54 at the beginning of the year. Since then, CERS shares have decreased by 11.7% and is now trading at $1.36.

How were Cerus' earnings last quarter?

Cerus Corporation (NASDAQ:CERS) released its earnings results on Thursday, May, 1st. The biotechnology company reported ($0.04) earnings per share for the quarter, beating analysts' consensus estimates of ($0.05) by $0.01. The biotechnology company earned $43.24 million during the quarter, compared to analyst estimates of $47.44 million. Cerus had a negative trailing twelve-month return on equity of 34.81% and a negative net margin of 10.23%.
Read the conference call transcript.

Who are Cerus' major shareholders?

Top institutional investors of Cerus include Bouvel Investment Partners LLC (0.25%), Wealth Enhancement Advisory Services LLC (0.04%), Pallas Capital Advisors LLC (0.03%) and Janney Montgomery Scott LLC (0.02%). Insiders that own company stock include William Mariner Greenman, Vivek K Jayaraman, Kevin Dennis Green, Richard J Benjamin, Chrystal Jensen, Carol Moore, Chrystal Menard, Eric Bjerkholt, Daniel N Swisher Jr, Ann Lucena and Hua Shan.
View institutional ownership trends.

How do I buy shares of Cerus?

Shares of CERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cerus own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cerus investors own include American Water Works (AWK), Waste Connections (WCN), DiamondRock Hospitality (DRH), The RMR Group (RMR), Voyager Therapeutics (VYGR), AU Optronics (AUOTY) and iShares Micro-Cap ETF (IWC).

Company Calendar

• Last Earnings: 5/01/2025
• Today: 7/18/2025
• Next Earnings (Estimated): 7/30/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Health Care Supplies
• Current Symbol: NASDAQ:CERS
• CIK: 1020214
• Web: www.cerus.com
• Phone: (925) 288-6000
• Fax: 925-288-6001
• Employees: 290
• Year Founded: 1991

Price Target and Rating

• Average Price Target for Cerus: $3.50
• High Price Target: $4.00
• Low Price Target: $3.00
• Potential Upside/Downside: +157.4%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.10)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$20.92 million
• Net Margins: -10.23%
• Pretax Margin: -10.15%
• Return on Equity: -34.81%
• Return on Assets: -9.68%

Debt

• Debt-to-Equity Ratio: 1.15
• Current Ratio: 2.32
• Quick Ratio: 1.63

Sales & Book Value

• Annual Sales: $180.27 million
• Price / Sales: 1.44
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.31 per share
• Price / Book: 4.39

Miscellaneous

• Outstanding Shares: 191,160,000
• Free Float: 180,455,000
• Market Cap: $259.98 million
• Optionable: Optionable
• Beta: 1.56